Related Experiment Video
Updated: Oct 16, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views
Gaetano Aurilio1, Matteo Santoni2, Francesco Massari3
1Medical Oncology Division of Urogenital and Head & Neck Cancer, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Background:
We address novelty regarding metabolomic profiling in renal cell carcinoma (RCC) patients, in an attempt to postulate potential treatment strategies.
Methods:
A large-scale literature search in existing scientific websites focusing on the keywords "renal cell carcinoma", "clear cell histology", "papillary histology", "metabolomic profiling", and "therapeutics" was performed. Results: The PI3K/Akt signaling pathway is key in clear cell RCC metabolism and accordingly several drugs are presently available for routine use in clinical practice. Along this line, new treatment combinations against PI3K/Akt family members are currently under clinical investigation. On the other hand, new developed targets such as c-Met tyrosine kinase domain, glutathione (GSH) metabolism, and histone deacetylases enzymes (HDAC), as well as therapeutic strategies targeting them are currently being tested in clinical trials and here discussed.
Conclusions:
In RCC patients, the PI3K/Akt signaling is still the most effective targetable pathway. Targeting other metabolic pathways such as c-Met, GSH, and HDAC appears to be a promising approach and deserve further insights.
Insights
Metabolomic profiling in renal cell carcinoma (RCC) reveals the PI3K/Akt pathway as a primary target. Emerging strategies targeting c-Met, glutathione (GSH), and histone deacetylases (HDAC) show promise for novel RCC therapeutics.
Area of Science:
- Oncology
- Metabolomics
- Pharmacology
Background:
- Renal cell carcinoma (RCC) patient metabolomics requires novel therapeutic strategies.
- Understanding RCC metabolism is crucial for developing targeted treatments.
Purpose of the Study:
- To explore metabolomic profiling in renal cell carcinoma (RCC).
- To identify and discuss potential therapeutic strategies for RCC based on metabolic pathways.
Main Methods:
- Comprehensive literature search on "renal cell carcinoma", "clear cell histology", "papillary histology", "metabolomic profiling", and "therapeutics".
- Analysis of existing and emerging therapeutic targets within RCC metabolism.
Main Results:
- The PI3K/Akt signaling pathway is central to clear cell RCC metabolism, with established clinical treatments.
- New therapeutic combinations targeting PI3K/Akt family members are in clinical investigation.
- Emerging targets include c-Met tyrosine kinase, glutathione (GSH) metabolism, and histone deacetylases (HDAC) with ongoing clinical trials.
Conclusions:
- The PI3K/Akt pathway remains the most effective targetable pathway in RCC.
- Targeting metabolic pathways like c-Met, GSH, and HDAC presents a promising avenue for future RCC therapies requiring further investigation.
More Related Videos
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
08:08Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015